To the Editor: Mild-to-severe thrombocytopenia is associated with COVID-19. It is encountered during the active immune dysregulated phase due to sepsis, drugs, and disseminated intravascular coagulation. In pediatric COVID-19, thrombocytopenia is seen in multisystemic inflammatory syndrome in children (MIS-C). Isolated thrombocytopenia, as in immune thrombocytopenia (ITP), is not part of case definitions of these complications of pediatric COVID-19 and is extremely rare [1]. Only two such cases have been reported previously. Both cases had mild COVID symptoms with no mucosal bleeds and responded well to IVIG and steroids [2, 3].
We report 1-y-5-mo-old well-looking female toddler, who presented with fever and ecchymoses over limbs for two week; with no hepatosplenomegaly, bone tenderness, or lymphadenopathy. She had history of mild COVID-19 five weeks back. Her platelet count was 20×109/L with giant platelets and no atypical cells. Other cell lines, biochemical parameters, coagulogram, infection workup, and inflammatory markers were normal. COVID-19 RT-PCR was negative. COVID-19 IgG antibodies were elevated (50.8 AU/mL) and IgM antibodies were normal. Hepatotropic viral markers, antinuclear antibody, and immunoglobulin profile were normal. She responded to single-dose intravenous immunoglobulin (IVIG) at 1 g/kg with platelets rising to 100×109/L after a week and normalizing at 10 wk. She has completed three months follow-up and continues in complete remission.
Our case highlights the need for clinicians to be aware of COVID-19–associated ITP in children and counsel the patient/parents on the identification of signs and symptoms of thrombocytopenia during recovery phase of COVID-19. Onset of thrombocytopenia 2–3 wk after COVID-19 infection with a negative RT-PCR, high titers of IgG antibodies to COVID-19 and nonfulfillment of MIS-C criteria should raise a suspicion of COVID-19–associated ITP. Diagnostic evaluation in newly diagnosed ITP in children should include COVID-19– antibody levels, in addition to the existing guidelines, to look for COVID-19 as etiological viral infection for ITP [4].
Data Availability
On request.
Declarations
Consent for Publication
Written informed consent was obtained from the patient's father.
Conflict of Interest
None.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Hoang A, Chorath K, Moreira A, et al. COVID-19 in 7780 pediatric patients: a systematic review. E Clinical Med. 2020;24:100433. [DOI] [PMC free article] [PubMed]
- 2.Soares ACCV, Loggetto SR, Manga FCM, Faustino LR, Braga JAP. Outcome of SARS-CoV-2 and immune thrombocytopenia in a pediatric patient. Hematol Transfus Cell Ther. 2021;43:101–103. doi: 10.1016/j.htct.2020.09.145. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Rosenzweig JD, McThenia SS, Kaicker S. SARS-CoV-2 infection in two pediatric patients with immune cytopenias: A single institution experience during the pandemic. Pediatr Blood Cancer. 2020;67:e28503 [DOI] [PMC free article] [PubMed]
- 4.Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3:3780–3817. doi: 10.1182/bloodadvances.2019000812. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
On request.